RESEARCH NOTE

Open Access



Prevalence and associated factors of uncontrolled hypertension among hypertensive patients: a nation-wide survey in Thailand

Boonsub Sakboonyarat^{1*}, Ram Rangsin¹, Anupong Kantiwong² and Mathirut Mungthin²

Abstract

Objectives: The objectives of the research were to determine the prevalence and factors associated of uncontrolled blood pressure among Thai hypertensive patients in a nationwide survey.

Results: A total of 65,667 patients with hypertension were included in this study. The greater proportion of participants, 40,834 (62.2%), were females. The average age of participants was 63.9 ± 11.1 years. Uncontrolled hypertension was detected among 16,122 patients (24.6%; 95% Cl 24.2–24.9). Among males and females, uncontrolled hypertension was 25.6% (95% Cl 25.1–26.2) and 23.9% (95% Cl 23.5–24.3) respectively. Multivariate analysis showed that the uncontrolled hypertension was significantly associated with being male, age, regions, hospital levels, diabetes comorbidity, higher body mass index, low density lipoprotein cholesterol level and the number of antihypertensive medications.

Keywords: Uncontrolled hypertension, Prevalence, Associated factors, Nationwide, Thailand

Introduction

Hypertension is one of the most common cardiovascular disorders worldwide. Globally, 30.8% of adults have hypertension, and the estimated prevalence of hypertension among males and females is 32.1% and 29.5%, respectively [1]. Hypertension is a major modifiable risk factor for heart diseases, stroke, end stage renal failure and peripheral vascular disease. The Thai National Health Examination Survey (NHES) 2004 and the NHES 2009 data indicated that it affects nearly one in every five Thai adults [2]. Information on controlling blood pressure (BP) is available worldwide, and the prevalence of controlled BP reported in the US, UK, China and Japan were 68.9%, 60.8%, 37.5% and 37.1%, respectively [1, 3]. However, limited information is available regarding the prevalence of uncontrolled hypertension in Thailand especially

*Correspondence: boonsub1991@pcm.ac.th

¹ Department of Military and Community Medicine, Phramongkutklao College of Medicine, Bangkok 10400, Thailand

Full list of author information is available at the end of the article



in nationwide studies. We aimed to use the information from the Thailand Diabetes Mellitus/Hypertension (DM/ HT) of the Medical Research Network of the Consortium of Thai Medical Schools (MedResNet) to determine BP control and risk factors associated with uncontrolled BP among Thai hypertensive patients from 2014 to 2015.

Main text

Methods

A nationwide, cross-sectional survey was conducted from 2014 to 2015. The survey aimed to determine outcomes among patients with hypertension visiting clinics in Bangkok supported by the Thailand National Health Security Office's (NHSO) program, private hospitals and public hospitals of the Ministry of Public Health (MoPH) in Thailand.

This study was reviewed and approved by the Royal Thai Army Medical Department and local institutional review boards of the participating hospitals. For selecting national representative samples of patients with hypertension in Thailand, a stratified two-stage cluster

© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/ publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

sampling method proportional to the size was conducted. For Bangkok, the targeted hospitals included all hospitals and clinics under the NHSO. However, all university hospitals were excluded.

Hypertensive patients aged \geq 18 years receiving medical treatment in a hospital, drawn from those sampling methods, during the previous 1 year were included. Any patient who had participated in a clinical trial was excluded. The number of participants totaled 65,667. The number of hospitals under the MoPH totaled 833 hospitals, including 717 community hospitals, 83 general hospitals and 33 regional hospitals. Hypertensive patients were selected by sampling and registered at each hospital. A standardized case report form was used to collect data from medical records of hypertensive treatment and was sent to the central data management unit. The data, including status of hypertensive complications and results of laboratory tests, were retrieved from patient's medical records.

Hypertension was defined by JNC's eight hypertension guidelines as high BP (SBP \geq 140 mmHg or DBP \geq 90 mmHg) and/or use of antihypertensive medicine [4]. Uncontrolled hypertension was defined by JNC's eight hypertension guidelines. The BP target is SBP < 140 mmHg or DBP < 90 mmHg among adults younger than 60 years and a BP goal of SBP < 150 mmHg and DBP < 90 mmHg in the general population aged \geq 60 years [4]. BMI was calculated as body weight in kilograms (kg) divided by height in meters squared [weight (kg)/height (m)²]. Waist circumferences were measure at the level of the umbilicus [5].

Data were coded, entered and analyzed using IBM SPSS Statistics for Windows, Version 23.0. Categorical data were presented as number and percentage, while continuous data were presented as mean and standard deviation (SD). Prevalence was analyzed using descriptive statistics and reported as percentage and 95% confidence interval. The Chi-square test was used to compare categorical data, while continuous data were compared using the *t*-test. The magnitude of association was presented as crude odds ratios (ORs) with 95% confidence interval. The final model with multivariate logistic regression analysis was created. A *p*-value < 0.05 was considered statistically significant.

Results

A total of 65,667 Thai patients with hypertension were enrolled in this study. The greater proportion of participants, 40,834 (62.2%), were females (Table 1). The average age of participants was 63.9 ± 11.7 years, while the average duration of hypertension was 6.5 ± 4.1 years. The average SBP was 133.6 ± 15.2 mmHg while the average DBP was 75.9 ± 10.6 mmHg. Overall prevalence of

Page 2 of 8

Table 1 Demographic characteristics of the enrolled Thaiadults with hypertension

Gender 40,834 (62.2 Male 24,833 (37.8 Age (years) (mean ± SD) 63.9 ± 11.7 20-29 98 (0.1) 30-39 1077 (1.6) 40-49 $6333 (9.7)$ 50-59 16,276 (24.8) 60-69 19,966 (30.4) 70-79 15,511 (23.6) 80-89 5832 (8.9) ≥ 90 456 (0.7) Region, n (%) Northeast Northeast 14,864 (22.6) Northern 18,032 (27.5) Central 23,104 (35.2) Southern 9667 (14.7) Hospital level 15,531 (23.6) First level 45,541 (69.4) Middle level 5096 (7.8) Healtcare coverage 101 Universal coverage scheme 48,747 (74.2) Government officer 13,181 (20.1) Social security scheme 2931 (45.5) Others 808 (1.2) Occupations 22,443 (34.2) Unemployed/retired 22,438 (34.2) Agriculturist	Variables	n (%)
Female 40,834 (62.2 Male 24,833 (37.8 Age (years) (mean ± SD) 63.9 ± 11.7 20-29 98 (0.1) 30-39 1077 (1.6) 40-49 6383 (9.7) 50-59 16,276 (24.8) 60-69 19,966 (30.4) 70-79 15,511 (23.6) 80-89 5832 (8.9) ≥ 90 456 (0.7) Region, n (%) 14,864 (22.6) Northeast 14,864 (22.6) Northern 18,032 (27.5) Central 23,104 (35.2) Southern 9667 (14.7) Hospital level 15,511 (23.6) First level 45,541 (69.4) Middle level 50.96 (7.8) Healthcare coverage 11.71 Universal coverage scheme 48,747 (74.2) Government officer 13,181 (20.1) Social security scheme 2931 (4.5) Others 808 (1.2) Occupations 22,649 (34.5) Officer 3220 (5.8) Others 22,649 (34.5) Officer 3220 (5.8)	Gender	
Male 24,833 (37.8 Age (years) (mean ± SD) 63.9 ± 11.7 20-29 98 (0.1) 30-39 1077 (1.6) 40-49 6383 (9.7) 50-59 16,276 (24.8) 60-69 19,966 (30.4) 70-79 15,511 (23.6) 80-89 5832 (8.9) ≥ 90 456 (0.7) Region, n (%) 14,864 (22.6) Northeast 14,864 (22.6) Northeast 14,864 (22.6) Northern 18,032 (27.5) Central 23,104 (35.2) Southern 9667 (14.7) Hospital level 15,030 (22.9) Standard/Advance level 45,541 (69.4) Middle level 15,030 (22.9) Standard/Advance level 45,741 (74.2) Government officer 13,181 (20.1) Social security scheme 2931 (4.5) Others 088 (1.2) Occupations 22,649 (34.2) Unemployed/retired 22,649 (34.5) Officer 3820 (5.8) Others 22,649 (34.5) Officer 3820 (5.8)	Female	40,834 (62.2)
Age (years) (mean ± SD) 63.9 ± 11.7 20-29 98 (0.1) 30-39 1077 (1.6) 40-49 6383 (9.7) 50-59 16,276 (24.8) 60-69 19,966 (30.4) 70-79 15,511 (23.6) 80-89 5832 (8.9) ≥ 90 456 (0.7) Region, n (%) 14,864 (22.6) Northeast 14,864 (22.6) Northern 18,032 (27.5) Central 23,104 (35.2) Southern 9607 (14.7) Hospital level First level First level 45,541 (69.4) Middle level 15,030 (22.9) Standard/Advance level 5096 (7.8) Healthcare coverage Universal coverage scheme Universal coverage scheme 48,747 (74.2) Government officer 13,181 (20.1) Social security scheme 2931 (4.5) Others 808 (1.2) Occupations 22,649 (34.5) Officer 326 (5.8) Others 22,649 (34.5) Officer 3820 (5.8) Others 5082 (Male	24,833 (37.8)
$20-29$ 98 (0.1) $30-39$ 1077 (1.6) $40-49$ 6383 (9.7) $50-59$ 16,276 (24.8) $60-69$ 19,966 (30.4) $70-79$ 15,511 (23.6) $80-89$ 5832 (8.9) ≥ 90 456 (0.7) Region, n (%) Northeast Northeast 14,864 (22.6) Northern 18,032 (27.5) Central 23,104 (35.2) Southern 9667 (14.7) Hospital level 15,030 (22.9) Standard/Advance level 5096 (7.8) Healthcare coverage 13,181 (20.1) Social security scheme 2931 (4.5) Others 808 (1.2) Occupations 22,649 (34.5) Unemployed/retired 22,649 (34.5) Officer 3220 (5.8) Others	Age (years) (mean \pm SD)	63.9 ± 11.7
30-39 10.71.6 40-49 6383 (9.7) 50-59 16.276 (24.8) 60-69 19.966 (30.4) 70-79 15.511 (23.6) 80-89 5832 (8.9) ≥ 90 456 (0.7) Region, n (%) 14,864 (22.6) Northeast 14,864 (22.6) Northern 18,032 (27.5) Central 23,104 (35.2) Southern 9667 (14.7) Hospital level 5096 (7.8) First level 45,541 (69.4) Middle level 5096 (7.8) Healthcare coverage 11,030 (22.9) Standard/Advance level 5096 (7.8) Healthcare coverage 11,001 Universal coverage scheme 48,747 (74.2) Government officer 13,181 (20.1) Social security scheme 2931 (4.5) Others 088 (1.2) Occupations 22,438 (34.2) Minepolyed/retired 22,438 (34.2) Agriculturist 3346 (5.1) Private business 22,649 (34.5) Officer 3820 (5.8) Others <t< td=""><td>20–29</td><td>98 (0.1)</td></t<>	20–29	98 (0.1)
40-49 638 (9.7) 50-59 16,276 (24.8) 60-69 19,966 (30.4) 70-79 15,511 (23.6) 80-89 5832 (8.9) ≥ 90 456 (0.7) Region, n (%) 14,864 (22.6) Northeast 14,864 (22.6) Northern 18,032 (27.5) Central 23,104 (35.2) Southern 9667 (14.7) Hospital level 15,511 (23.6) First level 45,541 (69.4) Middle level 5096 (7.8) Healthcare coverage 11,030 (22.9) Standard/Advance level 5096 (7.8) Healthcare coverage 11,181 (20.1) Social security scheme 2931 (4.5) Others 808 (1.2) Occupations 22,448 (34.2) Mindurits 3346 (5.1) Private business 22,649 (34.5) Officer 3820 (5.8) Others 2320 (5.8) Others 13,414 (20.4) Comorbidity 22,649 (34.5) Diabetes mellitus 8628 (13.1) Gout 5083 (7.7) <	30–39	1077 (1.6)
50-59 16,276 (24.8 60-69 19,966 (30.4 70-79 15,511 (23.6 80-89 5832 (8.9) ≥ 90 456 (0.7) Region, n (%) 14,864 (22.6 Northeast 14,864 (22.6 Northeast 14,864 (22.6 Northern 18,032 (27.5 Central 23,104 (35.2 Southern 18,032 (27.5 Healthcare 13,52 Standard/Advance level 5096 (7.8) Healthcare coverage 15,030 (22.9 Universal coverage scheme 48,747 (74.2 Government officer 13,181 (20.1 Social security scheme 22,438 (34.2 Agriculturist 3346 (5.1)	40–49	6383 (9.7)
60-69 19,966 (30.4 70-79 15,511 (23.6 80-89 5832 (8.9) ≥ 90 456 (0.7) Region, n (%) 14,864 (22.6 Northeast 14,864 (22.6 Southern 18,032 (27.5 Central 23,104 (35.2 Southern 18,032 (27.5 Holdbelevel 15,030 (22.9 Standard/Advance level 15,030 (22.9 Standard/Advance level 15,030 (22.9 Universal coverage scheme 48,747 (74.2 Government officer 13,181 (20.1 Social security scheme 22,438 (34.2 Agriculturist	50–59	16.276 (24.8)
70-79 15,511 (23.6 80-89 5832 (8.9) ≥ 90 456 (0.7) Region, n (%) 14,864 (22.6 Northeast 14,864 (22.6 Northern 18,032 (27.5 Central 23,104 (35.2 Southern 9667 (14.7) Hospital level 5,541 (69.4 First level 45,541 (69.4 Middle level 5,030 (22.9) Standard/Advance level 5096 (7.8) Healthcare coverage Universal coverage scheme Universal coverage scheme 48,747 (74.2) Government officer 13,181 (20.1) Social security scheme 2931 (4.5) Others 808 (1.2) Occupations 22,649 (34.5) Officer 326 (5.8) Others 320 (5.8) Others 326 (5.3) Others 322 (5.9) Opslipidemia 41,171 (62.7) Diabetes mellitus 8628 (13.1) Gout 5083 (7.7) Smoking 3035 (4.9) Never 50,733 (82.6 Ex-smoker 7624 (12.4)<	60–69	19.966 (30.4)
80-89 5832 (8.9) ≥ 90 456 (0.7) Region, n (%) 14,864 (22.6 Northeast 14,864 (22.6 Northern 18,032 (27.5 Central 23,104 (35.2 Southern 9667 (14.7) Hospital level 5 First level 45,541 (69.4 Middle level 5,030 (22.9) Standard/Advance level 5096 (7.8) Healthcare coverage 11,181 (20.1) Social security scheme 2931 (4.5) Others 808 (1.2) Occupations 22,438 (34.2) Agriculturist 3346 (5.1) Private business 22,649 (34.5) Officer 320 (5.8) Others 320 (5.8) Others 322 (5.9) Orbidity 346 (5.1) Private business 22,649 (34.5) Officer 320 (5.8) Others 346 (5.1) Private business 22,649 (34.5) Officer 3820 (5.8) Others 3820 (5.8) Others 5033 (7.7) Smo	70–79	15 511 (23 6)
bit OD 50.22 (0.7) ≥ 90 456 (0.7) Region, n (%) 14,864 (22.6 Northeast 14,864 (22.6 Northern 18,032 (27.5) Central 23,104 (35.2) Southern 9667 (14.7) Hospital level 5,541 (69.4) First level 45,541 (69.4) Middle level 5096 (7.8) Healthcare coverage 11,030 (22.9) Standard/Advance level 5096 (7.8) Healthcare coverage 13,181 (20.1) Social security scheme 2931 (4.5) Others 808 (1.2) Occupations 22,438 (34.2) Agriculturist 3346 (5.1) Private business 22,649 (34.5) Officer 3820 (5.8) Others 22,649 (34.5) Officer 3820 (5.8) Others 324 (5.3) Diabetes mellitus 8628 (13.1) Gout 50,733 (82.6 Ex-smoker 50,733 (82.6 Ex-smoker 7624 (12.4) Current smoker 3035 (4.9) Duration of hypertension (years)	80-89	5832 (8.9)
L 10 100 (0.1) Region, n (%) 14,864 (22.6 Northeast 14,864 (22.6 Northern 18,032 (27.5 Central 23,104 (35.2 Southern 9667 (14.7) Hospital level 5 First level 45,541 (69.4 Middle level 5096 (7.8) Healthcare coverage 11,030 (22.9) Standard/Advance level 5096 (7.8) Healthcare coverage 13,181 (20.1) Social security scheme 2931 (4.5) Others 808 (1.2) Occupations 22,438 (34.2) Agriculturist 3346 (5.1) Private business 22,649 (34.5) Officer 3820 (5.8) Others 232 (49.3) Others 13,414 (20.4) Comorbidity 22 Dyslipidemia 41,171 (62.7) Diabetes mellitus 8628 (13.1) Gout 50,733 (82.6 Ex-smoker 7024 (12.4) Current smoker 50,733 (82.6 Ex-smoker	> 90	456 (0.7)
Northeast 14,864 (22.6 Northern 18,032 (27.5 Central 23,104 (35.2 Southern 9667 (14.7) Hospital level 15,030 (22.9 First level 45,541 (69.4 Middle level 5096 (7.8) Healthcare coverage 5096 (7.8) Universal coverage scheme 48,747 (74.2 Government officer 13,181 (20.1 Social security scheme 2931 (4.5) Others 808 (1.2) Occupations 22,438 (34.2 Mirculturist 3346 (5.1) Private business 22,649 (34.5 Officer 3820 (5.8) Others 13,141 (20.4) Comorbidity 22,649 (34.5 Dyslipidemia 41,171 (62.7) Diabetes mellitus 8628 (13.1) Gout 5083 (7.7) Smoking 10 Never 50,733 (82.6) Ex-smoker 7624 (12.4) Current smoker 3035 (4.9) Duration of hypertension (years) (mean ± SD) 65 ± 4.1	\geq 50 Pagian n (%)	450 (0.7)
Northern 14,604 (22.0 Northern 18,032 (27.5 Central 23,104 (35.2 Southern 9667 (14.7) Hospital level 15,030 (22.9) First level 45,541 (69.4) Middle level 5096 (7.8) Healthcare coverage 5096 (7.8) Universal coverage scheme 48,747 (74.2) Government officer 13,181 (20.1) Social security scheme 2931 (4.5) Others 808 (1.2) Occupations 22,438 (34.2) Agriculturist 3346 (5.1) Private business 22,649 (34.5) Officer 3820 (5.8) Others 13,414 (20.4) Comorbidity 22,649 (34.5) Dyslipidemia 41,171 (62.7) Diabetes mellitus 8628 (13.1) Gout 5083 (7.7) Smoking 1041 (2.4) Never 50,733 (82.6) Ex-smoker 7624 (12.4) Current smoker 3035 (4.9) Duration of hypertension (years) (mean ± SD) 6.5 ± 4.	North cost	14.064 (22.6)
Normerin 16,052 (27.5) Central 23,104 (35.2) Southern 9667 (14.7) Hospital level 15,030 (22.9) First level 45,541 (69.4) Middle level 5096 (7.8) Healthcare coverage 5096 (7.8) Universal coverage scheme 48,747 (74.2) Government officer 13,181 (20.1) Social security scheme 2931 (4.5) Others 808 (1.2) Occupations 22,438 (34.2) Unemployed/retired 22,438 (34.2) Agriculturist 3346 (5.1) Private business 22,649 (34.5) Officer 3820 (5.8) Others 3820 (5.8) Others 13,414 (20.4) Comorbidity 22,649 (34.5) Dyslipidemia 41,171 (62.7) Diabetes mellitus 8628 (13.1) Gout 5083 (7.7) Smoking 20 Never 50,733 (82.6) Ex-smoker 7624 (12.4) Current smoker 3035 (4.9)	Northeast	14,804 (22.0)
Central 25,104 (53.2) Southern 9667 (14.7) Hospital level 45,541 (69.4) First level 45,541 (69.4) Middle level 5096 (7.8) Standard/Advance level 5096 (7.8) Healthcare coverage 13,030 (22.9) Universal coverage scheme 48,747 (74.2) Government officer 13,181 (20.1) Social security scheme 2931 (4.5) Others 808 (1.2) Occupations 22,438 (34.2) Unemployed/retired 22,438 (34.2) Agriculturist 3346 (5.1) Private business 22,649 (34.5) Officer 3820 (5.8) Others 3820 (5.8) Others 13,414 (20.4) Comorbidity 22,649 (34.5) Dyslipidemia 41,171 (62.7) Diabetes mellitus 8628 (13.1) Gout 5083 (7.7) Smoking 20,733 (82.6) Ex-smoker 7624 (12.4) Current smoker 3035 (4.9) Duration of hypertension (years) (mean ±SD	Control	18,052 (27.5)
Southern 9667 (14.7) Hospital level 45,541 (69.4 Middle level 15,030 (22.9 Standard/Advance level 5096 (7.8) Healthcare coverage 11,030 (22.9 Universal coverage scheme 48,747 (74.2 Government officer 13,181 (20.1 Social security scheme 2931 (4.5) Others 808 (1.2) Occupations 22,438 (34.2 Mgriculturist 3346 (5.1) Private business 22,649 (34.5) Officer 3820 (5.8) Others 13,414 (20.4) Comorbidity 22 Dyslipidemia 41,171 (62.7) Diabetes mellitus 8628 (13.1) Gout 5083 (7.7) Smoking 20 Never 50,733 (82.6) Ex-smoker 7624 (12.4) Current smoker 3035 (4.9) Duration of hypertension (years) (mean ±SD) 6.5 ±4.1	Central	23,104 (35.2)
Hospital level 45,541 (69.4 Middle level 15,030 (22.9 Standard/Advance level 5096 (7.8) Healthcare coverage 13,181 (20.1) Outversal coverage scheme 48,747 (74.2) Government officer 13,181 (20.1) Social security scheme 2931 (4.5) Others 808 (1.2) Occupations 22,438 (34.2) Miculturist 3346 (5.1) Private business 22,649 (34.5) Officer 3820 (5.8) Others 13,414 (20.4) Comorbidity 13,414 (20.4) Diabetes mellitus 8628 (13.1) Gout 5083 (7.7) Smoking 11,171 (62.7) Never 50,733 (82.6) Ex-smoker 7624 (12.4) Current smoker 3035 (4.9) Duration of hypertension (years) (mean ±SD) 6.5 ±4.1	Southern	9667 (14.7)
First level 45,541 (69.4 Middle level 15,030 (22.9 Standard/Advance level 5096 (7.8) Healthcare coverage 13,181 (20.1) Government officer 13,181 (20.1) Social security scheme 2931 (4.5) Others 808 (1.2) Occupations 22,438 (34.2) Middle business 22,649 (34.5) Officer 3820 (5.8) Others 3820 (5.8) Others 3820 (5.8) Others 13,414 (20.4) Comorbidity 13,414 (20.4) Dyslipidemia 41,171 (62.7) Diabetes mellitus 8628 (13.1) Gout 5083 (7.7) Smoking 1000000000000000000000000000000000000	Hospital level	
Middle level 15,030 (22.9) Standard/Advance level 5096 (7.8) Healthcare coverage 48,747 (74.2) Government officer 13,181 (20.1) Social security scheme 2931 (4.5) Others 808 (1.2) Occupations 20 Universal coverage scheme 48,747 (74.2) Government officer 13,181 (20.1) Social security scheme 2931 (4.5) Others 808 (1.2) Occupations 22,438 (34.2) Agriculturist 3346 (5.1) Private business 22,649 (34.5) Officer 3820 (5.8) Others 13,414 (20.4) Comorbidity 13,414 (20.4) Dyslipidemia 41,171 (62.7) Diabetes mellitus 8628 (13.1) Gout 5083 (7.7) Smoking 1000000000000000000000000000000000000	First level	45,541 (69.4)
Standard/Advance level 5096 (7.8) Healthcare coverage 48,747 (74,2) Government officer 13,181 (20.1) Social security scheme 2931 (4.5) Others 808 (1.2) Occupations 200 Unemployed/retired 22,438 (34.2) Agriculturist 3346 (5.1) Private business 22,649 (34.5) Officer 3820 (5.8) Others 13,414 (20.4) Comorbidity 314,412 (2.4) Dyslipidemia 41,171 (62.7) Diabetes mellitus 8628 (13.1) Gout 5083 (7.7) Smoking 2033 (82.6) Ex-smoker 7624 (12.4) Current smoker 3035 (4.9) Duration of hypertension (years) (mean ± SD) 6.5 ± 4.1	Middle level	15,030 (22.9)
Healthcare coverage 48,747 (74.2 Government officer 13,181 (20.1 Social security scheme 2931 (4.5) Others 808 (1.2) Occupations 22,438 (34.2) Agriculturist 3346 (5.1) Private business 22,649 (34.5) Officer 3820 (5.8) Others 03820 (5.8) Others 13,414 (20.4) Comorbidity 13,414 (20.4) Dyslipidemia 41,171 (62.7) Diabetes mellitus 8628 (13.1) Gout 5083 (7.7) Smoking 50,733 (82.6) Ex-smoker 7624 (12.4) Current smoker 3035 (4.9) Duration of hypertension (years) (mean ±SD) 6.5 ± 4.1	Standard/Advance level	5096 (7.8)
Universal coverage scheme 48,747 (74.2 Government officer 13,181 (20.1 Social security scheme 2931 (4.5) Others 808 (1.2) Occupations 22,438 (34.2 Agriculturist 3346 (5.1) Private business 22,649 (34.5) Officer 3820 (5.8) Others 04,1171 (62.7) Diabetes mellitus 8628 (13.1) Gout 5083 (7.7) Smoking 20,433 (34.2) Never 50,733 (82.6) Ex-smoker 7624 (12.4) Current smoker 3035 (4.9) Duration of hypertension (years) (mean ± SD) 6.5 ± 4.1	Healthcare coverage	
Government officer 13,181 (20.1 Social security scheme 2931 (4.5) Others 808 (1.2) Occupations 22,438 (34.2 Unemployed/retired 22,438 (34.2 Agriculturist 3346 (5.1) Private business 22,649 (34.5) Officer 3820 (5.8) Others 13,414 (20.4) Comorbidity 13,414 (20.4) Dyslipidemia 41,171 (62.7) Diabetes mellitus 8628 (13.1) Gout 5083 (7.7) Smoking 1000000000000000000000000000000000000	Universal coverage scheme	48,747 (74.2)
Social security scheme 2931 (4.5) Others 808 (1.2) Occupations 22,438 (34.2) Agriculturist 3346 (5.1) Private business 22,649 (34.5) Officer 3820 (5.8) Others 13,414 (20.4) Comorbidity 2 Dyslipidemia 41,171 (62.7) Diabetes mellitus 8628 (13.1) Gout 5083 (7.7) Smoking 2 Never 50,733 (82.6) Ex-smoker 7624 (12.4) Current smoker 3035 (4.9) Duration of hypertension (years) (mean ± SD) 6.5 ± 4.1	Government officer	13,181 (20.1)
Others 808 (1.2) Occupations 22,438 (34.2) Agriculturist 3346 (5.1) Private business 22,649 (34.5) Officer 3820 (5.8) Others 13,414 (20.4) Comorbidity 13,414 (20.4) Dyslipidemia 41,171 (62.7) Diabetes mellitus 8628 (13.1) Gout 5083 (7.7) Smoking 10,414 (20.4) Lever 50,733 (82.6) Ex-smoker 7624 (12.4) Current smoker 3035 (4.9) Duration of hypertension (years) (mean ± SD) 6.5 ± 4.1	Social security scheme	2931 (4.5)
Occupations 22,438 (34.2 Agriculturist 3346 (5.1) Private business 22,649 (34.5) Officer 3820 (5.8) Others 13,414 (20.4) Comorbidity 13,414 (20.4) Dyslipidemia 41,171 (62.7) Diabetes mellitus 8628 (13.1) Gout 5083 (7.7) Smoking 50,733 (82.6) Ex-smoker 7624 (12.4) Current smoker 3035 (4.9) Duration of hypertension (years) (mean ± SD) 6.5 ± 4.1	Others	808 (1.2)
Unemployed/retired 22,438 (34.2 Agriculturist 3346 (5.1) Private business 22,649 (34.5) Officer 3820 (5.8) Others 13,414 (20.4) Comorbidity 13,414 (20.4) Dyslipidemia 41,171 (62.7) Diabetes mellitus 8628 (13.1) Gout 5083 (7.7) Smoking 50,733 (82.6) Ex-smoker 50,733 (82.6) Ex-smoker 7624 (12.4) Current smoker 3035 (4.9) Duration of hypertension (years) (mean ± SD) 6.5 ± 4.1	Occupations	
Agriculturist 3346 (5.1) Private business 22,649 (34.5) Officer 3820 (5.8) Others 13,414 (20.4) Comorbidity 13,414 (20.4) Dyslipidemia 41,171 (62.7) Diabetes mellitus 8628 (13.1) Gout 5083 (7.7) Smoking 50,733 (82.6) Ex-smoker 7624 (12.4) Current smoker 3035 (4.9) Duration of hypertension (years) (mean ± SD) 6.5 ± 4.1	Unemployed/retired	22,438 (34.2)
Private business 22,649 (34.5 Officer 3820 (5.8) Others 13,414 (20.4) Comorbidity 13,414 (20.4) Dyslipidemia 41,171 (62.7) Diabetes mellitus 8628 (13.1) Gout 5083 (7.7) Smoking 50,733 (82.6) Ex-smoker 50,733 (82.6) Ex-smoker 7624 (12.4) Ourrent smoker 3035 (4.9) Duration of hypertension (years) (mean ± SD) 6.5 ± 4.1	Agriculturist	3346 (5.1)
Officer 3820 (5.8) Others 13,414 (20.4) Comorbidity 13,414 (20.4) Dyslipidemia 41,171 (62.7) Diabetes mellitus 8628 (13.1) Gout 5083 (7.7) Smoking 50,733 (82.6) Ex-smoker 50,733 (82.6) Ex-smoker 7624 (12.4) Ourrent smoker 3035 (4.9) Duration of hypertension (years) (mean ± SD) 6.5 ± 4.1	Private business	22,649 (34.5)
Others 13,414 (20.4) Comorbidity 41,171 (62.7) Diabetes mellitus 8628 (13.1) Gout 5083 (7.7) Smoking 50,733 (82.6) Ex-smoker 50,733 (82.6) Ex-smoker 7624 (12.4) Current smoker 3035 (4.9) Duration of hypertension (years) (mean ± SD) 6.5 ± 4.1	Officer	3820 (5.8)
Comorbidity 41,171 (62.7) Dyslipidemia 41,171 (62.7) Diabetes mellitus 8628 (13.1) Gout 5083 (7.7) Smoking 50,733 (82.6) Ex-smoker 50,733 (82.6) Current smoker 7624 (12.4) Ouration of hypertension (years) (mean ± SD) 6.5 ± 4.1	Others	13,414 (20.4)
Dyslipidemia 41,171 (62.7) Diabetes mellitus 8628 (13.1) Gout 5083 (7.7) Smoking 50,733 (82.6) Ex-smoker 50,733 (82.6) Current smoker 7624 (12.4) Duration of hypertension (years) (mean ± SD) 6.5 ± 4.1	Comorbidity	
Diabetes mellitus 8628 (13.1) Gout 5083 (7.7) Smoking 50,733 (82.6) Never 50,733 (82.6) Ex-smoker 7624 (12.4) Current smoker 3035 (4.9) Duration of hypertension (years) (mean ± SD) 6.5 ± 4.1	Dyslipidemia	41,171 (62.7)
Gout 5083 (7.7) Smoking 50,733 (82.6) Never 50,733 (82.6) Ex-smoker 7624 (12.4) Current smoker 3035 (4.9) Duration of hypertension (years) (mean ± SD) 6.5 ± 4.1	Diabetes mellitus	8628 (13.1)
Smoking 50,733 (82.6) Never 50,733 (82.6) Ex-smoker 7624 (12.4) Current smoker 3035 (4.9) Duration of hypertension (years) (mean ± SD) 6.5 ± 4.1	Gout	5083 (7.7)
Never 50,733 (82.6) Ex-smoker 7624 (12.4) Current smoker 3035 (4.9) Duration of hypertension (years) (mean ± SD) 6.5 ± 4.1	Smoking	
Ex-smoker 7624 (12.4) Current smoker 3035 (4.9) Duration of hypertension (years) (mean ± SD) 6.5 ± 4.1	Never	50,733 (82.6)
Current smoker $3035 (4.9)$ Duration of hypertension (years) (mean \pm SD) 6.5 ± 4.1	Ex-smoker	7624 (12.4)
Duration of hypertension (years) (mean \pm SD) 6.5 ± 4.1	Current smoker	3035 (4.9)
	Duration of hypertension (years) (mean \pm SD)	6.5 ± 4.1
Blood pressure (mmHa)	Blood pressure (mmHa)	
SBP (mean + SD) 132.6 ± 15.2	SBP (mean \pm SD)	132.6 ± 15.2
DBP (mean + SD) 75.9 ± 10.6	DBP (mean + SD)	759+106
Waist circumference (cm) 86.3 + 10.8	Waist circumference (cm)	863+108
$\frac{1}{249 \pm 47}$	$BMI (kg/m^2)$ (mean \pm SD)	249+47
27.9 ± 7.7	< 25	27.2 - 7.7
>25 25_20 00 25_20 00	> 2520.00	24,127 (24.1) 20 707 (22)
20,797 (55) 30_34.00 cocc (10.1)	20_34.00	20,777 (33)
> 25 1751 (2.0)	> 25 > 25	1761 (20)

Table 1 (continued)

Variables	n (%)
Biochemical measurements (mean \pm SD)	
Serum uric acid (mg/dL)	6.1 ± 1.8
TC (mg/dL)	193.7±44.7
TG (mg/dL)	150.9±89.2
HDL (mg/dL)	50.7 ± 15.6
LDL (mg/dL)	115.1 ± 36.8
Estimated GFR (mL/min/1.73 m ²)	71±23.6
≥90	13,678 (23.7)
60–89	25,263 (43.8)
30–59	16,418 (28.4)
15–29	1649 (2.9)
< 15	731 (1.3)
Number of antihypertensive medications	
0	1110 (1.7)
1	26,153 (39.8)
2	27,175 (41.4)
≥3	11,229 (17.1)

SD standard deviation, *mmHg* millimeter of mercury, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *cm* centimeter, *FPG* fasting plasma glucose, *TC* total cholesterol, *TG* triglyceride, *HDL*, high-density lipoprotein cholesterol, *LDL* low-density lipoprotein cholesterol, *BMI* body mass index, *eGFR* estimated alomerulus filtration rate

uncontrolled hypertension in the study was 24.6% (95% CI 24.2-24.9). Among males and females, uncontrolled hypertension was 25.6% (95% CI 25.1-26.2) and 23.9% (95% CI 23.5-24.3), respectively. Univariate and multivariate analysis were performed to determine factors associated with uncontrolled hypertension (Tables 2 and 3). The final model was adjusted for sex, age, regions, hospital levels, smoking, diabetes mellitus (DM) comorbidity, duration of hypertension, BMI, LDL level and the number of antihypertensive medications used. After adjusting, the factors associated with uncontrolled hypertension comprised being male, regions, hospital levels, DM comorbidity, higher BMI, higher LDL level and higher number of antihypertensive medications used; however, higher age was a protective factor for uncontrolled hypertension.

Discussion

These results revealed important implications to the Thai public health system because hypertension is a major risk factor for cerebrovascular events and cardiovascular diseases. A secondary intervention is necessary to reduce any complications. This study comprised the largest research in Southeast Asia, focusing on uncontrolled hypertension. The present nationwide survey from 2014 to 2015 showing the prevalence of uncontrolled hypertension among Thai adults with hypertension was 24.6%. The prevalence of uncontrolled hypertension in the current study was lower than that previously reported for US and China [6, 7]. However, in Thailand one related study in 2009 reported the prevalence of uncontrolled hypertension was 75.6% [2]. Thus, in the present study, the prevalence of uncontrolled hypertension was lower than that in the 2009 survey. This situation could be explained by several points. Firstly, the related study [2] was conducted by a national health examination in a field survey while the present study was conducted among hypertensive patients receiving medical treatment in a hospital. In 2012, Thai guidelines on treating hypertension were released to direct any physician including general practitioners and specialists. Therefore, Thai patients with hypertension have been receiving appropriate medical treatment. Consequently, patients with hypertension, who follow-up with their physicians, have obtained more proper medical care. In the present study, patients with hypertension obtaining medical treatment in hospitals under the MoPH all over Thailand were enrolled. However, those with high BP treated at primary care units or university hospitals were not included in the current study; thus, the prevalence of uncontrolled hypertension may be underestimated.

The present study showed that patients with hypertension at higher ages tended to be at lower risk for uncontrolled hypertension, similar to other studies [7, 8]. Hypertensive complications and end organ damage will not occur in the early period of hypertension. Thus, younger hypertensive patients lack awareness of complications; moreover, working age people may not follow up their appointment with medical doctors resulting from the available time mismatch between working age patients and healthcare services [9]. However, some studies have shown that the prevalence of uncontrolled hypertension among elderly hypertensive patients was more likely to be higher [10-12]. Similarly, some related studies conducted in the US and China revealed that males had a higher risk for uncontrolled hypertension than females [10, 13-15] due to biological factors [16] including hormonal effects on increased BP. These related studies have shown that females have lower prorenin and renin levels than males, causing BP among males to be higher than females [16, 17]. Nevertheless, another study reported hypertension could be better controlled among males [18].

Our findings showed that the prevalence of uncontrolled hypertension differed by region. In the northeast area, the prevalence of uncontrolled hypertension was significantly lower than that in other regions. The finding could be explained by behavioral and local cultural factors. Patients in this area enjoyed consuming vegetable and fruits, which may have decreased body adiposity

Variables	Normotension	Uncontrolled HT	Crude	95% CI	<i>p</i> -value
	n (%)	n (%)	Odds ratio		
Gender					
Female	31,077 (76.1)	9757 (23.9)	1		
Male	18,468 (74.4)	6365 (25.6)	1.10	(1.06-1.14)	< 0.001
Age (years)	64.9 ± 11.4	60.7 ± 12.2	0.97	(0.97-0.97)	< 0.001
20–29	48 (49.0)	50 (51.0)	1		
30–39	625 (58.0)	452 (42.0)	0.69	(0.46-1.05)	0.084
40–49	4064 (63.7)	2319 (36.3)	0.55	(0.37–0.82)	0.003
50–59	10,811 (66.4)	5465 (33.6)	0.49	(0.33-0.72)	< 0.001
60–69	16,251 (81.4)	3715 (18.6)	0.22	(0.15-0.33)	< 0.001
70–79	12,613 (81.3)	2898 (18.7)	0.22	(0.15-0.33)	< 0.001
80–89	4697 (80.5)	1135 (19.5)	0.23	(0.16-0.35)	< 0.001
≥90	384 (84.2)	72 (15.8)	0.18	(0.11–0.29)	< 0.001
Region					
Northeast	11,813 (79.5)	3051 (20.5)	1		
Northern	13,717 (76.1)	4315 (23.9)	1.22	(1.16–1.28)	< 0.001
Central	17,101 (74.0)	6003 (26.0)	1.36	(1.29–1.43)	< 0.001
Southern	6914 (71.5)	2753 (28.5)	1.54	(1.45–1.64)	< 0.001
Hospital level					
First level	35,160 (77,2)	10.381 (22.8)	1		
Middle level	10.668 (71.0)	4362 (29.0)	1.39	(1.33-1.44)	< 0.001
Standard/advance level	3717 (72.9)	1379 (27.1)	1.26	(1.18–1.34)	< 0.001
Healthcare coverage				(
Universal coverage scheme	36.881 (75.7)	11.866 (24.3)	1		
Government officer	10.193 (77.3)	2988 (22.7)	0.91	(0.87-0.95)	< 0.001
Social security scheme	1903 (64 9)	1028 (35.1)	1.68	(1 55–1 82)	< 0.001
Others	568 (70.3)	240 (29.7)	1.31	(1.13–1.53)	< 0.001
Occupations	500 (70.5)	210 (2507)	1.01	(1110 1100)	(0.00)
Unemployed/retired	17809(794)	4629 (20.6)	1		
Agriculturist	2387 (71 3)	959 (28.7)	1 5 5	(1 43–1 68)	< 0.001
Private business	17 266 (76 2)	5383 (23.8)	1.55	(1.15-1.25)	< 0.001
Officer	2706 (70.8)	1114 (29 2)	1.20	(1.47-1.71)	< 0.001
Others	9377 (69.9)	4037 (30.1)	1.50	(1.58–1.74)	< 0.001
Dyslinidemia	5577 (05.5)	1037 (30.1)	1.00	(1.50 1.7 1)	< 0.001
No	18 345 (74 9)	6151 (25.1)	1		
Yes	31 200 (75.8)	9971 (24.2)	0.95	(0.92-0.99)	0.010
Diabetes mellitus	51,200 (75.0)	5571 (21.2)	0.95	(0.92 0.99)	0.010
No	/3 311 (75 0)	13 728 (24 1)	1		
Yes	6234 (723)	2394 (27.7)	1 21	(1 15–1 28)	< 0.001
Gout	0231(72.3)	2001(27.7)	1.2 1	(1.15 1.20)	< 0.001
No	45 755 (75 5)	1/ 820 (2/ 5)	1		
Voc	3700 (74.6)	14,029 (24.3)	1 05	(0.00, 1.1.2)	0.126
Smoking	57 90 (74.0)	1295 (25.4)	1.05	(0.99-1.12)	0.120
Never	38 552 (76 0)	12 181 (24 0)	1		
Ex smoker	50,552 (70.0)	12,101 (24.0)	0.00	(0.04 1.05)	0.951
	2202 (70.1)	833 (27 /)	1.20	(0.24-1.03)	0.001
	2202(12.0)	61 ± 10	0.00	(1.10-1.30)	< 0.001
Waist circumforance (cm)	0.0 ± 4.1 85 8 ± 10 6	U.4 工 4.U 87 8 上 11 1	0.99	(0.90-0.99)	< 0.001
$\frac{1}{2} \sum_{i=1}^{n} \frac{1}{2} \sum_{i=1}^{n} \frac{1}$	0.0 ± 10.0	07.0 ± 11.1	1.02	(1.01=1.02)	< 0.001
ылі (Kg/m²)	24.0±4.5	25.9±4.9	1.06	(1.06-1.06)	< 0.001

Table 2 Univariate analysis for factors associated with uncontrolled hypertension among Thai adults with hypertension

Table 2 (continued)

Variables	Normotension	Uncontrolled HT	Crude	95% CI	<i>p</i> -value
	n (%)	n (%)	Odds ratio		
<25	27,156 (79.6)	6981 (20.4)	1		
25–29.99	15,227 (73.2)	5570 (26.8)	1.42	(1.37–1.48)	< 0.001
30–34.99	4309 (67.5)	2077 (32.5)	1.88	(1.77–1.99)	< 0.001
≥35	1048 (59.9)	703 (40.1)	2.61	(2.36–2.88)	< 0.001
Biochemical measurements					
Serum uric acid (mg/dL)	6.1 ± 1.8	6.2 ± 1.9	1.04	(1.03-1.06)	< 0.001
TC (mg/dL)	192.3 ± 43.1	198.1 ± 49.0	1.01	(1.00-1.01)	< 0.001
TG (mg/dL)	148.8±87.3	157.5 ± 94.6	1.01	(1.00-1.01)	< 0.001
HDL (mg/dL)	50.7 ± 15.8	50.8 ± 15.2	1.01	(1.00-1.01)	0.467
LDL (mg/dL)	114.0 ± 36.4	118.5 ± 38.1	1.01	(1.00-1.01)	< 0.001
Estimated GFR (mL/min/1.73 m ²)	70.2 ± 23.2	73.7 ± 24.7	1.01	(1.00-1.01)	< 0.001
≥90	9732 (71.2)	3946 (28.8)	1		
60–89	19,314 (76.5)	5949 (23.5)	0.76	(0.73–0.80)	< 0.001
30–59	12,974 (79.0)	3444 (21.0)	0.66	(0.62–0.69)	< 0.001
15–29	1274 (77.3)	375 (22.7)	0.73	(0.64–0.82)	< 0.001
< 15	511 (69.9)	220 (30.1)	1.06	(0.90-1.25)	0.469
Number of antihypertensive medications	i				
0	930 (83.8)	180 (16.2)	1		
1	20,717 (79.2)	5436 (20.8)	1.36	(1.15–1.60)	< 0.001
2	20,148 (74.1)	7027 (25.9)	1.80	(1.53–2.12)	< 0.001
≥3	7750 (69.0)	3479 (31.0)	2.32	(1.97–2.73)	< 0.001
Drug classes (monotherapy)					
ARB	1953 (76.6)	595 (23.4)	1		
ACEI	5520 (77.1)	1644 (22.9)	0.98	(0.88–1.09)	0.678
Anti-adrenergic	2060 (78.4)	566 (21.6)	0.90	(0.79–1.03)	0.121
Diuretics	2697 (80.9)	635 (19.1)	0.77	(0.68–0.88)	< 0.001
CCBs	8301 (81.2)	1921 (18.8)	0.76	(0.68–0.84)	< 0.001

SD standard deviation, mmHg millimeter of mercury, SBP systolic blood pressure, DBP diastolic blood pressure, cm centimeter, FPG fasting plasma glucose, TC total cholesterol, TG triglyceride, HDL, high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol, BMI body mass index, eGFR estimated glomerulus filtration rate, ARB angiotensin receptor blockers, ACEI angiotensin converting enzyme inhibitors; anti-adrenergic; alpha and beta blockers, CCBs, calcium channel blockers

levels, consequently reducing BP [19–21]. Nevertheless, after adjusting, both residing in northeast Thailand and BMI were associated with controlled BP. Another explanation is that northeast Thailand is mainly an agricultural area. As a result, the patients with hypertension in this area are agriculturists; moreover, traditional dancing and playing of northeastern Thai games creates more physical activities. More physical activities can decrease both systolic and diastolic BP including decreased risks for high BP [22, 23]. Our study has shown that hypertensive patients receiving medical treatment at middle level hospitals and standard/advanced level hospitals tended to indicate a higher prevalence of uncontrolled hypertension compared with those at first level hospitals. Similarly, one related study in Kenya illustrated that hypertensive patients in provincial hospitals could control their BP more effectively than those in national hospitals [24]. Patients with uncontrolled hypertension in first level hospitals may be referred to high potential hospitals for proper medical management. Consequently, high level hospitals are permeated with hypertensive patients with poorly controlled BP.

The study reported hypertensive patients with diabetes comorbidity were associated with BP control. This result was similar to that of related studies in Europe [25, 26], showing that diabetes was associated with a high risk of poor BP control. This effect may have resulted from insulin resistance and endothelial dysfunction; thus, increasing BP [27–29]. Several studies reported similar results with this study revealing a relationship between BMI and controlled BP [30–33]. The study found that patients with hypertension presenting BMI more than 25 kg/m² tended to be higher at risk of uncontrolled BP. Notably, patients with BMI > 35 kg/m² were 1.7 times at higher

Table	3 Multivariate	analysis	for	factors	ass	ociated
with	uncontrolled	hypertensi	on	among	Thai	adults
with b	nypertension					

Variables	Adjusted odds ratio	95% CI	<i>p</i> -value
Gender			
Female	1		
Male	1.16	(1.10–1.20)	< 0.001
Age (years)	0.97	(0.97–0.97)	< 0.001
Region			
Northeast	1		
Northern	1.21	(1.14–1.29)	< 0.001
Central	1.20	(1.13–1.28)	< 0.001
Southern	1.48	(1.38–1.59)	< 0.001
Hospital level			
First level	1		
Middle level	1.23	(1.16–1.30)	< 0.001
Standard/advance level	1.12	(1.03–1.22)	0.009
Diabetes mellitus			
No	1		
Yes	1.16	(1.08–1.23)	< 0.001
Smoking			
Never	1		
Ex-smoker	1.04	(0.96-1.11)	0.334
Current smoker	1.08	(0.97–1.19)	0.155
Duration of hypertension (years)	1.00	(0.99–1.01)	0.120
BMI (kg/m ²)			
< 25	1		
25–29.99	1.19	(1.13–1.24)	< 0.001
30–34.99	1.42	(1.32–1.52)	< 0.001
≥35	1.70	(1.51–1.92)	< 0.001
LDL (mg/dL)			
< 100	1		
>100	1.17	(1.11–1.22)	< 0.001
Number of antihypertensive medi	cations		
0	1		
1	1.39	(1.13–1.70)	0.002
2	1.80	(1.47–2.20)	< 0.001
≥3	2.32	(1.89–2.86)	< 0.001

LDL low-density lipoprotein cholesterol, BMI body mass index

Adjusted for gender, age, regions, hospital levels, diabetes comorbidity, smoking status, duration of hypertension, body mass index, LDL level and number of antihypertensive medications

risk when compared with those with BMI < 25 kg/m². This finding could be attributed among most patients with higher BMI defined as obesity. Most patients with obesity have high adiposity levels. The adipocytes are substrate for producing leptin, resulting in increased leptin level, leading to heightened sympathetic nerve activity, contributing to elevated BP [34, 35]. The present study reported that increasing LDL level was associated

with uncontrolled hypertension. Our findings agree with related studies [26, 36, 37] supporting the relationship between the cholesterol level and increased BP. Evidence supports the results that LDL cholesterol elevation leads to increased stability of mRNA for AT1 receptors regarding angiotensin II. Moreover, LDL density at vascular level is proportional to cholesterolemia, contributing to vasoconstriction and pressure in response to angiotensin II infusion [38].

Our data showed a relationship between increasing amounts of antihypertensive medications used and uncontrolled BP, firstly, illustrating that other studies reported similar results, followed by various factors [39, 40]. Patients experiencing difficulty controlling BP are likely to be treated with multiple medications. Therefore, this result might be a consequence of uncontrolled hypertension. However, we found that some patients with hypertension without using antihypertensive medication could control their BP.

The strength of this study includes its nationwide scope for uncontrolled hypertension, the largest sample size in Southeast Asia. Thus, the findings of the study could be generalized and applied in similar hypertension populations. One implication of the study is to reduce the prevalence of uncontrolled hypertension, resulting from improving hypertension management. Moreover, hypertensive patients should control their modifiable risk factors. Healthcare services access of hypertensive patients especially at working age should be adjusted for appropriate situations. Above all, MoPH's managers and physicians should provide further preventative strategies to attenuate cardiovascular risk factors.

Limitations

The study employed a cross-sectional design, and as such, the results could show only factors associated with uncontrolled hypertension. The data presented in the present study were obtained in the 2014 to 2015 Thailand DM/HT of the NHSO from MedResNet central data management, so we were aware of missing data from this observational study. However, this represents a relatively large sample size and some data were missing as from the nationwide observational study, so associations between factors and outcomes could be presented.

Abbreviations

DM: diabetes mellitus; HT: hypertension; SBP: systolic blood pressure; DBP: diastolic blood pressure; CI: confidence interval; BMI: body mass index; MoPH: Ministry of Public Health; NHSO: National Health Security Office; SD: standard deviation; GFR_EPI: glomerular infiltration rate calculated by epidemiology collaboration formula; Hb: hemoglobin; Hct: hematocrit; LDL: low density lipoprotein cholesterol; HDL: high density lipoprotein cholesterol; TG: triglyceride; TC: total cholesterol.

Acknowledgements

The authors wish to thank the entire staff members of the Department of Military and Community Medicine, Phramongkutklao College of Medicine, for their support in completing this study. The Thai DM/HT study and the Medical Research Network of the Consortium of Thai Medical Schools (MedResNet) were supported by The Thailand National Health Security Office.

Authors' contributions

BS designed and managed the project, collected and analyzed data and composed the manuscript. RR designed and managed the project and reviewed/ edited the manuscript. AK reviewed/edited the manuscript. MM designed the project and reviewed/edited the manuscript. All the authors participated in approving the final draft of the manuscript. All authors read and approved the final manuscript.

Funding

No funding was received.

Availability of data and materials

The datasets generated and/or analyzed during the current study are available at http://www.damus.in.th after the permission of the Thailand DM/HT study of the Medical Research Network of the Consortium of Thai Medical Schools (MedResNet).

Ethics approval and consent to participate

The data of this study were retrieved from databases: an assessment in Quality of Care among Patients Diagnosed with Type 2 Diabetes and Hypertension Visiting the Ministry of Public Health and Bangkok Metropolitan Administration Hospital in Thailand (Thailand DM/HT) after receiving permission from the Medical Research Network of the Consortium of Thai Medical Schools (MedResNet). The Thailand DM/HT was approved by local institutional review boards of the participating hospitals. The participants provided written consent in agreement with the WMA Declaration of Helsinki—Ethics principles for medical research involving human subjects. This study was reviewed and approved by the Royal Thai Army Medical Department Institutional Review Board, Reference Number S060h/60_Exp.

Consent for publication

This manuscript includes details and images not relating to any individual person.

Competing interests

The authors declare that they have no competing interests.

Author details

¹ Department of Military and Community Medicine, Phramongkutklao College of Medicine, Bangkok 10400, Thailand. ² Department of Pharmacology, Phramongkutklao College of Medicine, Bangkok 10400, Thailand.

Received: 4 May 2019 Accepted: 29 June 2019 Published online: 04 July 2019

References

- Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441–50.
- Aekplakorn W, Sangthong R, Kessomboon P, Putwatana P, Inthawong R, Taneepanichskul S, et al. Changes in prevalence, awareness, treatment and control of hypertension in Thai population, 2004–2009: thai National Health Examination Survey III–IV. J Hypertens. 2012;30(9):1734–42.
- Wang Z, Chen Z, Zhang L, Wang X, Hao G, Zhang Z, et al. Status of hypertension in China: results from the China hypertension survey, 2012–2015. Circulation. 2018;137(22):2344–56.
- 4. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8)2014 Guideline

for Management of High Blood Pressure 2014 Guideline for Management of High Blood Pressure. JAMA. 2014;311(5):507–20.

- Organization WH. Waist circumference and waist-hip ratio: report of a WHO expert consultation. Geneva. 2008;8–11:2011.
- Yoon SS, Fryar CD, Carroll MD. Hypertension prevalence and control among adults: United States, 2011–2014: US Department of Health and Human Services, Centers for Disease Control; 2015.
- Wang J, Zhang L, Wang F, Liu L, Wang H, China National Survey of Chronic Kidney Disease Working G. Prevalence, awareness, treatment, and control of hypertension in China: results from a national survey. Am J Hypertens. 2014;27(11):1355–61.
- Hu L, Huang X, You C, Li J, Hong K, Li P, et al. Prevalence and risk factors of prehypertension and hypertension in southern China. PLoS ONE. 2017;12(1):e0170238.
- Meelab S, Bunupuradah I, Suttiruang J, Sakulrojanawong S, Thongkua N, Chantawiboonchai C, et al. Prevalence and associated factors of uncontrolled blood pressure among hypertensive patients in the rural communities in the central areas in Thailand: a cross-sectional study. PLoS ONE. 2019;14(2):e0212572.
- Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;345(7):479–86.
- Peng S, Shen T, Liu J, Tomlinson B, Sun H, Chen X, et al. Uncontrolled hypertension increases with age in an older community-dwelling chinese population in Shanghai. Aging Dis. 2017;8(5):558–69.
- Khanam MA, Lindeboom W, Razzaque A, Niessen L, Smith W, Milton AH. Undiagnosed and uncontrolled hypertension among the adults in rural Bangladesh: findings from a community-based study. J Hypertens. 2015;33(12):2399–406.
- Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124(9):1046–58.
- 14. Khosravi A, Pourheidar B, Roohafza H, Moezzi M, Mousavi M, Hajiannejad A, et al. Evaluating factors associated with uncontrolled hypertension: Isfahan cohort study, Iran. ARYA Atheroscler. 2014;10(6):311–8.
- Gu D, Reynolds K, Wu X, Chen J, Duan X, Muntner P, et al. Prevalence, awareness, treatment, and control of hypertension in china. Hypertension (Dallas, Tex: 1979). 2002;40(6):920–7.
- Sandberg K, Ji H. Sex differences in primary hypertension. Biol Sex Diff. 2012;3(1):7.
- Danser AH, Derkx FH, Schalekamp MA, Hense HW, Riegger GA, Schunkert H. Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. J Hypertens. 1998;16(6):853–62.
- Hicks LS, Fairchild DG, Horng MS, Orav EJ, Bates DW, Ayanian JZ. Determinants of JNC VI guideline adherence, intensity of drug therapy, and blood pressure control by race and ethnicity. Hypertension (Dallas, Tex: 1979). 2004;44(4):429–34.
- Streppel MT, Arends LR, van Veer P, Grobbee DE, Geleijnse JM. Dietary fiber and blood pressure: a meta-analysis of randomized placebo-controlled trials. Arch Intern Med. 2005;165(2):150–6.
- Whelton SP, Hyre AD, Pedersen B, Yi Y, Whelton PK, He J. Effect of dietary fiber intake on blood pressure: a meta-analysis of randomized, controlled clinical trials. J Hypertens. 2005;23(3):475–81.
- Morenga LT, Williams S, Brown R, Mann J. Effect of a relatively highprotein, high-fiber diet on body composition and metabolic risk factors in overweight women. Eur J Clin Nutr. 2010;64(11):1323–31.
- 22. Bento VF, Albino FB, Moura KF, Maftum GJ, Santos Mde C, Guarita-Souza LC, et al. Impact of physical activity interventions on blood pressure in Brazilian populations. Arq Bras Cardiol. 2015;105(3):301–8.
- Huai P, Xun H, Reilly KH, Wang Y, Ma W, Xi B. Physical activity and risk of hypertension: a meta-analysis of prospective cohort studies. Hypertension (Dallas, Tex: 1979). 2013;62(6):1021–6.
- Mutua EM, Gitonga MM, Mbuthia B, Muiruri N, Cheptum JJ, Maingi T. Level of blood pressure control among hypertensive patients on follow-up in a regional referral hospital in Central Kenya. Pan Afr Med J. 2014;18:278.
- Kjeldsen SE, Naditch-Brule L, Perlini S, Zidek W, Farsang C. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey. J Hypertens. 2008;26(10):2064–70.

- Cordero A, Bertomeu-Martinez V, Mazon P, Facila L, Bertomeu-Gonzalez V, Cosin J, et al. Factors associated with uncontrolled hypertension in patients with and without cardiovascular disease. Rev Esp Cardiol. 2011;64(7):587–93.
- Yanai H, Tomono Y, Ito K, Furutani N, Yoshida H, Tada N. The underlying mechanisms for development of hypertension in the metabolic syndrome. Nutr J. 2008;7:10.
- Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006;113(15):1888–904.
- Meigs JB, Larson MG, Fox CS, Keaney JF Jr, Vasan RS, Benjamin EJ. Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: the Framingham Offspring Study. Diabetes Care. 2007;30(10):2529–35.
- Dua S, Bhuker M, Sharma P, Dhall M, Kapoor S. Body mass index relates to blood pressure among adults. N Am J Med Sci. 2014;6(2):89–95.
- Droyvold WB, Midthjell K, Nilsen TI, Holmen J. Change in body mass index and its impact on blood pressure: a prospective population study. Int J Obes. 2005;29(6):650–5.
- Chorin E, Hassidim A, Hartal M, Havakuk O, Flint N, Ziv-Baran T, et al. Trends in adolescents obesity and the association between BMI and blood pressure: a cross-sectional study in 714,922 healthy teenagers. Am J Hypertens. 2015;28(9):1157–63.
- Abebe SM, Berhane Y, Worku A, Getachew A. Prevalence and associated factors of hypertension: a crossectional community based study in northwest ethiopia. PLoS ONE. 2015;10(4):e0125210.
- Hall JE, Brands MW, Hildebrandt DA, Kuo J, Fitzgerald S. Role of sympathetic nervous system and neuropeptides in obesity hypertension. Braz J Med Biol Res. 2000;33(6):605–18.

- Haynes WG, Morgan DA, Walsh SA, Mark AL, Sivitz WI. Receptormediated regional sympathetic nerve activation by leptin. J Clin Invest. 1997;100(2):270–8.
- Cicero AF, Rosticci M, Baronio C, Morbini M, Parini A, Grandi E, et al. Serum LDL cholesterol levels and new onset of arterial hypertension: an 8-year follow-up. Eur J Clin Invest. 2014;44(10):926–32.
- Laaksonen DE, Niskanen L, Nyyssönen K, Lakka TA, Laukkanen JA, Salonen JT. Dyslipidaemia as a predictor of hypertension in middle-aged men. Eur Heart J. 2008;29(20):2561–8.
- Strehlow K, Wassmann S, Bohm M, Nickenig G. Angiotensin AT1 receptor over-expression in hypercholesterolaemia. Ann Med. 2000;32(6):386–9.
- Knight EL, Bohn RL, Wang PS, Glynn RJ, Mogun H, Avorn J. Predictors of uncontrolled hypertension in ambulatory patients. Hypertension (Dallas, Tex 1979). 2001;38(4):809–14.
- Kim KI, Kim Y, Kim HJ, Kang DH, Park JB, Choi DJ, et al. Current status and characteristics of hypertension treatment by primary physicians in Korea: data from Korean epidemiology study on hypertension (KEY study). Am J Hypertens. 2008;21(8):884–9.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

